Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 18/20 | 0.71 |
| ▸ | NPY1R | P25929 | 11/20 | 0.71 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.71 |
| ▸ | NPY2R | P49146 | 7/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4441700 | 1.00 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29770018 | 1.00 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30713829 | 1.00 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL4439081 | 1.00 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31710585 | 1.00 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL3484757 | 1.00 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30567513 | 1.00 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL4441735 | 1.00 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL4439114 | 1.00 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL3485342 | 1.00 | NPY4R (0.71) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590321-B2 | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof | EXUMA BIOTECH CORP. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12325728-B2 | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of CD79A and CD79B | EXUMA BIOTECH CORP. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20220340927-A1 | METHODS AND COMPOSITIONS FOR THE MODIFICATION AND DELIVERY OF LYMPHOCYTES | EXUMA BIOTECH CORP. (US) | 2022-10-27 | — | — | US | disclosed |
| US-20220306698-A1 | METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES TO EXPRESS POLYPEPTIDES COMPRISING THE INTRACELLULAR DOMAIN OF CD79A AND CD79B | EXUMA BIOTECH CORP. (US) | 2022-09-29 | — | — | US | disclosed |
| EP-4022035-A1 | METHODS AND COMPOSITIONS FOR THE MODIFICATION AND DELIVERY OF LYMPHOCYTES | EXUMA BIOTECH CORP. (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11325948-B2 | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL | EXUMA BIOTECH CORP. (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590321-B2 | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof | CD4, PBK, CD69 | NPY4R 3705/4885NPY1R 3246/4885NPY5R 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.